Works by Saillard, C.


Results: 11
    1
    2

    A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 6, p. 1, doi. 10.1038/s41408-020-0330-5
    By:
    • Collignon, A.;
    • Hospital, M. A.;
    • Montersino, C.;
    • Courtier, F.;
    • Charbonnier, A.;
    • Saillard, C.;
    • D'Incan, E.;
    • Mohty, B.;
    • Guille, A.;
    • Adelaïde, J.;
    • Carbuccia, N.;
    • Garnier, S.;
    • Mozziconacci, M. J.;
    • Zemmour, C.;
    • Pakradouni, J.;
    • Restouin, A.;
    • Castellano, R.;
    • Chaffanet, M.;
    • Birnbaum, D.;
    • Collette, Y.
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.

    Published in:
    European Journal of Haematology, 2024, v. 112, n. 4, p. 530, doi. 10.1111/ejh.14140
    By:
    • Petit, C.;
    • Saillard, C.;
    • Mohty, B.;
    • Hicheri, Y.;
    • Villetard, F.;
    • Maisano, V.;
    • Charbonnier, A.;
    • Rey, J.;
    • D'Incan, E.;
    • Rouzaud, C.;
    • Gelsi‐Boyer, V.;
    • Murati, A.;
    • Lhoumeau, A. C.;
    • Ittel, A.;
    • Mozziconacci, M. J.;
    • Alary, A. S.;
    • Hospital, M.‐A.;
    • Vey, N.;
    • Garciaz, S.
    Publication type:
    Article